LexisNexis® Legal Newsroom
New Jersey Jury Awards $2M In 1 Accutane Case, Finds For Defense In 2 Others

ATLANTIC CITY, N.J. - (Mealey's) A New Jersey state court jury on April 8 awarded a plaintiff $2.1 million after finding that Hoffman-La Roche Inc.'s acne drug Accutane was a substantial factor in causing her inflammatory bowel disease (IBD) and that the company failed to adequately warn her...

New Jersey Accutane Judge Denies Defendant Roche's Motion To Recuse For Bias

ATLANTIC CITY, N.J. - (Mealey's) The judge overseeing New Jersey's Accutane litigation on Feb. 13 denied a motion by defendant Hoffman-La Roche Inc. to recuse, refuting allegations that she is biased in favor of plaintiffs and stating that in this litigation, defense counsel are "less respectful...

New Jersey Jury Awards $1.58M In Retrial Of Accutane Bowel Injury Case

ATLANTIC CITY, N.J. — (Mealey’s) A New Jersey state court jury on March 11 found that Hoffman-La Roche failed to adequately warn that its former acne drug Accutane could cause ulcerative colitis and awarded the plaintiff $1,587,928 for past medical expenses and for pain and suffering ( Kamie...

N.J. Accutane Judge: Post-2002 Warnings Of Bowel Injury Are Adequate Under Law

ATLANTIC CITY, N.J. — (Mealey’s) A judge overseeing New Jersey’s Accutane litigation on April 2 granted summary judgment to Accutane manufacturer Hoffman-La Roche after finding that as a matter of law, the drug’s post-April 2002 warnings about inflammatory bowel disease (IBD)...